Is OS Therapies going out of business?

OS Therapies Inc (OSTX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

OS Therapies Inc (OSTX) scores 14 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 65.01% (YoY)

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $205K of cash and short-term investments against $14.7M of annual burn. Adjusted shares outstanding increased 65.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

0% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 65.01% (YoY)
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.01y
• Return on Assets: -290.52%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-09-10.

Price as of 2026-09-26.